Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

Company Overview

Eyepoint Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery. Both products leverage sustained-release technology to deliver corticosteroids directly to ocular tissues, aiming to reduce treatment frequency and improve patient compliance compared with traditional eye drop approaches.

The company secured FDA approvals for both YUTIQ and DEXYCU in late 2018 and commenced U.S. commercial launches in 2019. Eyepoint is headquartered in New York, with additional facilities supporting manufacturing and clinical development efforts. Since its inception, the company has entered into multiple licensing agreements to expand its product portfolio and explore new ophthalmic indications, while also advancing preclinical programs investigating sustained-release therapies for other retinal and anterior segment disorders.

Eyepoint is led by James A. Mazzo, who serves as Chairman, President, and Chief Executive Officer. Under his leadership, the company has built a specialized commercial organization and forged strategic collaborations to broaden its market reach. Eyepoint continues to invest in research and development to enhance its sustained-release platform and pursue additional regulatory milestones that may address unmet needs in ophthalmology.

Key Stats

• Today's Range: $11.38 to $12.07
• 50-Day Range: $9.41 to $12.04
• 52-Week Range: $3.91 to $13.98
• Volume: 742,789 shs
• Average Volume: 618,499 shs
• Market Capitalization: $818.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.86
• Consensus Rating: Buy

Eyepoint Pharmaceuticals Stock Analysis - MarketRank™

Eyepoint Pharmaceuticals scored higher than 37% of companies evaluated by MarketBeat, and ranked 631st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Eyepoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eyepoint Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Eyepoint Pharmaceuticals are expected to decrease in the coming year, from ($2.13) to ($2.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eyepoint Pharmaceuticals is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eyepoint Pharmaceuticals is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eyepoint Pharmaceuticals has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.16% of the outstanding shares of Eyepoint Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Eyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in Eyepoint Pharmaceuticals has recently increased by 11.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eyepoint Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eyepoint Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.16% of the outstanding shares of Eyepoint Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Eyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in Eyepoint Pharmaceuticals has recently increased by 11.29%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.43

News Sentiment

Eyepoint Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Eyepoint Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eyepoint Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.46% of the stock of Eyepoint Pharmaceuticals is held by insiders.

Percentage Held by Institutions

99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EYPT Stock Analysis - Frequently Asked Questions

How have EYPT shares performed this year?

Eyepoint Pharmaceuticals' stock was trading at $7.45 at the beginning of the year. Since then, EYPT shares have increased by 59.5% and is now trading at $11.88.

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) issued its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by $0.18. The company had revenue of $5.33 million for the quarter, compared to analysts' expectations of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative trailing twelve-month return on equity of 63.80%.
Read the conference call transcript.

When did Eyepoint Pharmaceuticals' stock split?

Shares of Eyepoint Pharmaceuticals reverse split on the morning of Wednesday, December 9th 2020.The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Eyepoint Pharmaceuticals' major shareholders?

Eyepoint Pharmaceuticals' top institutional investors include Adage Capital Partners GP L.L.C. (9.87%), Federated Hermes Inc. (6.67%), Franklin Resources Inc. (6.25%) and Patient Square Capital LP (1.97%). Insiders that own company stock include Ew Healthcare Partners, LP, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine and David R Guyer.
View institutional ownership trends.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eyepoint Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eyepoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/05/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:EYPT
• CIK: 1314102
• Web: eyepointpharma.com
• Phone: (617) 926-5000
• Fax: 617-926-5050
• Employees: 120
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Eyepoint Pharmaceuticals: $26.86
• High Price Target: $33.00
• Low Price Target: $18.00
• Potential Upside/Downside: +126.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$130.87 million
• Net Margins: -337.93%
• Pretax Margin: -337.58%
• Return on Equity: -63.80%
• Return on Assets: -50.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.00
• Quick Ratio: 7.91

Sales & Book Value

• Annual Sales: $43.27 million
• Price / Sales: 18.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.93 per share
• Price / Book: 2.41

Miscellaneous

• Outstanding Shares: 68,930,000
• Free Float: 65,853,000
• Market Cap: $818.89 million
• Optionable: Optionable
• Beta: 1.93